LGALS2 and atherosclerosis: Although validated results are limited, it was proposed that blocking galectin-2 with selective antibodies or nanobody clones would be an excellent strategy to target galectin-2-mediated collateral arteriogenesis, myocardial infarction, immune cell adhesion, inflammation, and T-cell apoptosis in atherosclerosis (317).